Education＆ScienceWebinars
Asthma Assembly Symposium
Share:
Saturday 28 November 2020
- 16:00-17:45 (UTC+9
This webinar has ended.
Chairs
Dr Kang-Yun Lee
Assembly Head
Dr Phuong Phan Thu
Assembly Head-Elect
Dr Shih-Lung Cheng
Assembly Deputy Head
Programme
Dr Yoichi Nakanishi
Introduction
APSR President
Prof. Hao-Chien Wang
The Risk of Short-Acting Beta-Agonist Over-reliance
the AVM’s main presentation, by Prof. Hao-Chien Wang, National Taiwan University Hospital, Taiwan
Dr Keiko Kan-o
Incense smoke induces airway hyperresponsiveness, alterations of tight junction proteins and loss of airway epithelial barrier integrity via oxidative stress
Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan
Winner of the Gold Award for this symposium
Dr Tsunahiko Hirano
Airway TNF-LIGHT expression and associated molecular inflammatory profiles in asthma patients with persistent airflow limitation
Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Japan
Winner of a Silver Award for this symposium
Dr Noriyuki Tashima
Elevated serum free fatty acids may be a risk factor of adult onset asthma: Nagahama Study
Department of Respiratory Medicine, Graduate School of Medicine Kyoto University, Japan
Winner of a Silver Award for this symposium
Dr Duminda Yasaratne
Epidemiology of bronchial asthma during pregnancy: A cross-sectional study of pregnant women attending antenatal clinic at Teaching Hospital Peradeniya, Sri Lanka
Department of Medicine, Faculty of Medicine, University of Peradeniya, Sri Lanka
Summary
by the APSR Asthma Assembly leadersDr Kang-Yun Lee, Assembly Head
Dr Phuong Phan Thu, Assembly Head-Elect
Dr Shih-Lung Cheng, Assembly Deputy Head
Questions for panelists and their responses
Whether FENO has any role in personalized treatment of asthma?
Dr Hao-Chien Wang responds:
FeNO is a marker of eosinophilic inflammation & TH2 inflammation of airway. It could be used as a composite marker when we try to consider using biologics, another clinical application is to monitor the patient’s compliance of ICS.
How to control asthma in adult patient who always use reliever often? In which they don’t want to use a controller due to iya cost
Dr Hao-Chien Wang responds:
Considering over use (over reliance) of SABA, the most important thing is patient education: We should emphasize the importance of controller usage (for better symptom control, improved asthma related clinical outcomes, less healthcare resource utilization) and the risk of SABA overuse (poor asthma control, risk of acute exacerbation & increased mortality). Another strategy is try to use formoterol/ICS (anti-inflammatory reliever) for these patients (SMART approach).
Is there still a benefit of Montelukast for asthma patients?
Dr Hao-Chien Wang responds:
Leukotriene modifier (Montelukast) has some role in asthma treatment:
- asthmatic with allergic rhinitis,
- exercise induced asthma,
- as add on therapy with other controllers (ICS, ICS+LABA) for better asthma control.
may i know at what stage of pregnancy you have recorded the high incidence of asthma symptoms?
Dr Duminda Yasaratne responds:
usually at mid-second week. There were another few who developed symptoms close to term. Thanks.